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Abstract
Sparsely tested group of platinum nanoparticles (PtNPs) may have a comparable effect as
complex platinum compounds. The aim of this study was to observe the effect of PtNPs in in
vitro amplification of DNA fragment of phage λ, on the bacterial cultures (Staphylococcus
aureus), human foreskin fibroblasts and erythrocytes. In vitro synthesized PtNPs were char-
acterized by dynamic light scattering (PtNPs size range 4.8–11.7 nm), zeta potential mea-
surements (-15 mV at pH 7.4), X-ray fluorescence, UV/vis spectrophotometry and atomic
absorption spectrometry. The PtNPs inhibited the DNA replication and affected the second-
ary structure of DNA at higher concentrations, which was confirmed by polymerase chain
reaction, DNA sequencing and DNA denaturation experiments. Further, cisplatin (CisPt), as
traditional chemotherapy agent, was used in all parallel experiments. Moreover, the encap-
sulation of PtNPs in liposomes (LipoPtNPs) caused an approximately 2.4x higher of DNA
damage in comparison with CisPt, LipoCisPt and PtNPs. The encapsulation of PtNPs in
liposomes also increased their antibacterial, cytostatic and cytotoxic effect, which was deter-
mined by the method of growth curves on S. aureus and HFF cells. In addition, both the
bare and encapsulated PtNPs caused lower oxidative stress (determined by GSH/GSSG
ratio) in the human erythrocytes compared to the bare and encapsulated CisPt. CisPt was
used in all parallel experiments as traditional chemotherapy agent.
Introduction
The first anticancer drug cisplatin (cis-diamminedichloroplatinum(II)) was discovered in 1965
by Rosenberg during his studies on the effects of an electric current on bacterial growth [1].
The binding of cisplatin to DNA and the interactions with non-DNA targets with subsequent
triggering of cell death through apoptosis, necrosis or both belong to the most important
parameters of cisplatin cytotoxicity [2]. Since then, numerous platinum complexes of second
generation (carboplatin, oxaliplatin, nedaplatin) and third generation (lobaplatin, heptaplatin)
have been developed [3] and evaluated as anticancer agents [4, 5]. The undesired side effects
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can be eliminated by specific molecular interactions of a drug with cancer cells and by selective
targeting, which can be done by their encapsulation in the molecules suitable for selective
transportation. The most common transporters belong to functionalized polymers, nanoparti-
cles with conjugated platinum drugs, carbon nanotubes and micelles. Among them, liposomes,
which consist of a phospholipid bilayer surrounding an aqueous core, are a very important
class of compounds [6]. Liposomes have interesting biological activities including effective
drug loading capacity, biocompatibility and improved pharmacokinetics. The liposomal for-
mulations of cisplatin and oxaliplatin (Lipoplatin™ and Lipoxal™) are now widely used to
reduce drug toxicity and also improve drug targeting [7, 8]. Experimentally, many nanoparti-
cles consisting of the polymers or copolymers and the Pt-based drugs have been tested.
Among these, polyethylene glycol-functionalized poly-isobutylene-maleic acid copolymer can
form complexes with cisplatin. The nanoparticles are internalized into the endolysosomal
compartment of cancer cells releasing cisplatin in a pH-dependent manner. These nanoparti-
cles have been developed for better antitumor efficacy, which was confirmed in a 4T1 breast
cancer model in vivo with limited nephrotoxicity [9]. Furthermore, the nanoparticles treat-
ment resulted in reduced systemic and nephrotoxicity, which was confirmed by the decreased
biodistribution of platinum in kidney [10, 11]. The nanoparticles of oxaliplatin and carbopla-
tin with polyisobutylene maleic acid copolymer with glucosamine and albumin-bound pacli-
taxel, respectively, were also tested [12, 13].
Plenty of studies discuss the effects of halogenated Pt salts and complexes and are reviewed
elsewhere [14–16], whereas the effects of PtNPs are not mostly elucidated. It was found that
PtNPs have anti-oxidant and anti-inflammatory effects. In this case, the platinum nanoparti-
cles are able to scavenge superoxide anion radical (O2
-) and hydroxyl radical (OH) [11, 17, 18]
and this ability was also shown for the PtNPs within apoferritin [19, 20]. The ability of the
PtNPs to scavenge the reactive oxygen species was studied in mouse ischemic brain. The treat-
ment with PtNPs significantly improved motor function and greatly reduced the infarct vol-
ume, especially in the cerebral cortex [21, 22]. The effects of the PtNPs of sizes of 20, 100 and
more than 100 nm on HT29 have been confirmed and have been found to cause DNA strand
breaks in a concentration, time and size-dependent manner, but appear not to translocate into
the nucleus or interact with mitochondria [23].
The interaction of Pt-attached iron oxide nanoparticles with DNA of was studied previously
using gel electrophoresis and transmission electron microscopy. Two types of interactions
were suggested in this case: the first interaction involved the direct linkage of DNA molecules
onto the surface of the nanoparticles, while the second interaction was suggested to be the
detachment of small PtNPs from the iron oxide support by the strong DNA interaction [24,
25]. On the other hand, the PtNPs did not show cytotoxicity in several different cultured cells
(TIG-1, MI-38, MRC-5, HeLa, and HepG2) [17]. The contradiction of these studies indicates
that the biological effects of PtNPs remains unclear and seems to be dependent on the particle
size and most probably surface properties.
The interaction of different nanoparticles (NPs) with bacteria and fungi was studied by
Chwalibog et al. and Sawosz et al. [26, 27]. It was found that silver, gold, and PtNPs, with nega-
tive zeta potential, had cell damaging properties on Staphylococcus aureus (Gram-positive bac-
teria) and Candida albicans (fungi). The analysis of morphological effects of the interaction of
PtNPs with Listeria monocytogenes (Gram-positive) by transmission electron microscopy
(TEM) revealed that the PtNPs entered into the cells of Listeria monocytogenes. The authors
even stated that the nanoparticles were located close to DNA and probably bound to it. In the
case of Salmonella enteritidis (Gram-negative), the PtNPs probably bound to DNA. This was
studied by confocal microscopy with Nomarski contrast and fluorescent DAPI labelling.
After washing and centrifugation, the PtNPs-DNA complexes were characterized. The results
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indicated that the bacteria could be used as a transporter to deliver PtNPs to the specific points
in the body [27, 28].
In this work, we present our results on the preparation of liposome with encapsulated plati-
num derivatives both PtNPs and cisplatin (CisPt). The aim of this study was to investigate the
effect of these PtNPs on in vitro amplification of DNA fragment of phage λ, and on the bacte-
rial cultures (Staphylococcus aureus), human foreskin fibroblasts (HFF) and erythrocytes.
Materials and methods
Chemicals and material
Cholesterol, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt, chloroform,
cisplatin, PtCl4, polyvinylpyrrolidone (PVP, 40 k), HCl (37%, w/w), NaBH4 and water were
purchased from Sigma-Aldrich (St. Louis, MO, USA) in ACS purity. Hydrogenated phosphati-
dylcholine from soybean was a gift from Lipoid GMBH (Ludwigshafen, Germany). The deio-
nised water was prepared using Aqual 25 (Aqual, Brno, Czech Republic) and was further
purified using apparatus MilliQ Direct QUV equipped with the UV lamp (Merck Millipore,
Merck KgaA, Darmstadt, Germany). The pH of the solutions was measured using a pH meter
WTW inoLab (WTW GmbH, Weilheim, Germany).
Preparation of PtNPs
The PtNPs were prepared according to Oh et al. [29] with a slight modification. The PtNPs
were also covered by polyvinylpyrrolidone (PVP), in order to prevent their aggregation [30].
Briefly, PtCl4 (0.034 g) was dissolved in acidic water (5 mL) with 16 μL of 37% HCl. The solu-
tion of PtCl4 (5 mL) was added, with stirring, to another solution of 0.135 g PVP in water (45
mL). The mixture was stirred for 1 h at 25˚C. After the addition of NaBH4 (50 mg) the final
colour of the solution became black. The mixture was stirred overnight. Prepared particles
were characterized as described in S1 Text.
Preparation of liposome film
The liposomes were prepared according to the published method [31] with necessary modifi-
cations [32]. Briefly, cholesterol (100 mg), 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol)
sodium salt (100 mg) and phosphatidylcholine (100 mg) were dissolved in chloroform (4.5
mL). A lipid film was obtained by rotary evaporation of chloroform. The residual chloroform
was removed by nitrogen.
Preparation of liposome filled with PtNPs (LipoPtNPs)
The solutions containing 0, 0.015, 0.03131, 0.0625, 0.125, 0.25, 0.5 or 1 mL of platinum nano-
particles (PtNPs, 400 μg/mL of Pt) were diluted with water to 1 mL and added to liposome (20
mg). The samples were homogenized for 15 min in an ultrasonic bath Sonorex Digital 10P
(Bandelin, Berlin, Germany). The homogenized mixtures were then heated and shaken for 15
min at 60˚C using a Thermomixer Comfort (Eppendorf, Germany). The samples were then
washed several times with water employing Amicon 3k centrifugation filters (Merck Millipore,
Merck KgaA, Darmstadt, Germany) with a final sample volume of 1 mL [32].
Preparation of liposome filled with cisplatin (LipoCisPt)
The solutions containing 0, 0.015, 0.03131, 0.0625, 0.125, 0.25, 0.5 or 1 mL of cisplatin (CisPt,
0.4 mg Pt per mL) were diluted with water to 1 mL and added to liposome (20 mg). The
samples were prepared according to the same procedure described in paragraph above.
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Polymerase chain reaction (PCR)
Taq PCR kit was purchased from New England Biolabs (Ipswitch, MA, USA). The forward
and reverse primers for the amplification of λ xis gene fragment were synthesized by Sigma-
Aldrich and their sequences were 5'-CCTGCTCTGCCGCTTCACGC-3' and 5'-TCCGGA
TAAAAACGTCGATGACATTTGC-3', respectively. The volume of the reaction mixture was
25 μL, which was composed of 2.5 μL of 10× standard Taq reaction buffer, 0.5 μL of 1 mM
deoxynucleotide solution, 0.5 μL of each of the primers (10 μM), 0.125 μL of Taq DNA poly-
merase; selected volume of water or drugs diluted with water (sterile, ACS purity, Sigma-
Aldrich) and 0.5 μL of bacteriophage λ DNA.
The PCR was performed using Mastercycler ep realplex4 S (Eppendorf, AG, Hamburg, Ger-
many) with the following cycling conditions: initial denaturation for 120 s at 95˚C; 30 cycles of
PCR (15 s at 95˚C, 15 s at 64˚C and 45 s at 72˚C) with a final elongation for 5 min at 72˚C. The
obtained DNA fragments (498 bp) were purified by MinElute PCR Purification Kit (Qiagen,
Germany). The DNA concentration was determined spectrophotometrically.
Agarose gel electrophoresis
The amplified product was analysed using agarose gel electrophoresis and the working condi-
tions were as follows: 2% agarose gel (High melt/Medium fragment, Mercury, San Diego, CA,
USA) with 1× TAE buffer, 60 V and 160 min (Bio-Rad, Hercules, CA, USA). The 100 bp DNA
ladder (New England Biolabs, Ispwich, MA, USA) was used as a molecule size marker. The
bands were visualized using UV transilluminator at 312 nm (Vilber-Lourmat, Marne-la-Vallée
Cedex, France).
The fluorescence intensity of the ethidium bromide was detected by In-Vivo Xtreme (Care-
stream Health Inc., Rochester, NY, USA). The parameters were as follows: Excitation filter:
520 nm; Emission filter: 600 nm; Exposure time: 6 s; Binning: 2 × 2, f-Stop: 1.1; and Field of
View: 19.5 × 19.5 cm. The images were processed by Carestream Molecular Software. The fluo-
rescence was quantified using software and the background was subtracted. The intensity of
the fluorescence of ethidium bromide was directly proportional to the concentration of the
DNA.
DNA sequencing
The purified DNA fragments (50 μg/mL) were mixed with different concentrations of PtNPs
(25, 50, 100, 200 and 400 μg/mLPt) in a ratio of 1:1 (v/v). The solutions of DNA with PtNPs
were incubated for 1 h at 25˚C (Thermomixer 5355, Eppendorf, Germany). To remove the
excess of PtNPs, a dialysis was performed for 12 h at 6˚C using 0.025 μm membrane filter
(Millipore, Ireland) with ACS water.
CisPt interactions with DNA
The solution of the DNA fragments (50 μg/mL) was mixed with different concentrations of
cisplatin (25, 50, 100, 200 and 400 μg/mLPt) in a rate of 1:1 (v/v) in the environment of 10 mM
NaClO4. The solutions of DNA with the drugs were incubated for 24 h at 37˚C. To remove the
excess of the platinum-based drug a dialysis was performed for 24 h at 6˚C using a 0.025 μm
membrane filter (Millipore, Ireland).
Sequencing of platinated DNA
The conditions of sequencing reaction were as described elsewhere [33].
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Comet assay
The comet assay was performed according to Singh et al. [34] with small modifications [24,
35]. Conventional slides were immersed in 0.5% normal-melting agarose (v/v, CLP, San
Diego, USA) and dried at 50˚C. The cells and slides were handled under dimmed light condi-
tions during the whole process. Briefly, 75 μL of 0.5% low-melting agarose was mixed with
approximately 10000 cells suspended in 10 μL of PBS and layered onto the slides and immedi-
ately covered with coverslips. After agarose solidification (5 min at 4˚C), the coverslips were
removed and the slides were immersed overnight in dark at 4˚C in freshly prepared lysing
solution (2.5 M NaCl, 100 mM Na2EDTA, 10 mM Tris, pH 10) containing 1% Triton X-100
and 10% DMSO (v/v). After the lysis, the slides were placed on a horizontal gel electrophoresis
unit filled with electrophoretic buffer (300 mM NaOH, 1mM Na2EDTA, pH> 13) and left
there for 30 min in dark at 4˚C for DNA unwinding. Then, the electrophoresis was performed
for 30 min at 1.25 V/cm (300 mA). After the electrophoresis, the slides were washed with neu-
tralizing buffer (0.4 M Tris, pH 7.5) and the slides were stained with 2 μg/mL of ethidium bro-
mide for 5 min in dark at 25˚C. After the staining, the slides were washed with distilled water,
covered with coverslips and imaged by a microscope using the inverted system fluorescence
microscope Olympus IX 71S8F-3 (Tokyo, Japan). The excitation filter 520–550 nm and the
emission filter of 580 nm were employed (Magnification: 100×) in this experiment. The images
were captured by Camera Olympus DP73 and processed by Stream Basic 1.7 Software with the
resolution of 4800 × 3600 pixels. From each slide, 10 fields were taken and the nuclei were clas-
sified in five categories ranging from 0 (no visible tail) to 4 (most DNA in tail). To quantify the
effect of the drugs on DNA damage, an index of damage (ID) was calculated as a sum of the
numbers of the nuclei in each category multiplied with 0.1 for category 0 and by 1, 2, 3 and 4
for other categories divided by total number of the nuclei.
ID ¼
0:1 N0 þ 1N1 þ 2N2 þ 3N3 þ 4N4
N0 þ N1 þN2 þN3 þN4
Cultivation of Staphylococcus aureus
Staphylococcus aureus (NCTC 8511) was obtained from the Czech Collection of Microorgan-
isms, Faculty of Science, Masaryk University, Brno, Czech Republic. The strains of the bacte-
rium were stored as a spore suspension in 20% (v/v) glycerol at −20˚C according to the
conditions mentioned in Chudobova et al. [36, 37]. Prior to use in this study, the strains were
thawed and the glycerol was removed by washing with distilled water. The cultivation medium
contained: meat peptone (5 g/L), NaCl (5 g/L), bovine extract (1.5 g/L), yeast extract (1.5 gL)
(HIMEDIA, Mumbai, India), and sterilized MilliQ water with 18 MO. Before sterilization, the
pH of the cultivation medium was adjusted to 7.4 and the media were sterilized at 121˚C for
30 min in a sterilizer (Tuttnauer 2450EL, Israel). The prepared cultivation media was inocu-
lated with the bacterial culture into 25 mL Erlenmeyer flasks and subsequently the bacterial
cultures were cultivated for 24 h on a shaker at 600 rpm and 37˚C. The cultivated bacterial cul-
tures were diluted by the cultivation medium to the optical density (OD600) = 0.1 AU and used
in the following experiments [38].
Growth curves
The antimicrobial effect of the tested compounds was analysed by measuring the absorbance
using an apparatus Multiskan EX (Thermo Fisher Scientific, Germany) according to Chudo-
bova et al. [39]. Briefly, the concentrations of the platinum compounds (PtNPs and/or
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cisplatin) were 0, 0.5, 1.0, 1.9, 3.8, 7.5, 15, 30 and 60 μg/mL of Pt. The obtained results were
recalculated to relative absorbance value, thus the control growth curve without the addition
of the platinum derivatives refers to 100%. The values less than 100% indicated relative cell
death.
Cultivation of human foreskin fibroblast
Human Foreskin Fibroblast (HFF) cell line was obtained from ATCC Cell Lines (Wesel, Ger-
many). HFF cell line was grown as monolayers in DMEM (high glucose) medium with 10%
foetal bovine serum, supplemented with penicillin and streptomycin (1 U per mL) at 37˚C in
5% CO2 atmosphere. Approximately 2 × 105 cells at logarithmic growth phase were treated
with free and/or encapsulated CisPt or PtNPs in concentrations 0, 12.5, 25, 50, 100 and
200 μg/mL of Pt for 2h, and harvested using a cell-scraper and resuspended in 200 μL of PBS.
After the treatment, the cells were harvested using a cell-scraper and resuspended in 200 μL of
PBS. All the experiments were performed in two replicates. HFF were also used for Comet
assay.
Cell growth and proliferation assay of HFF using impedance
measurement with xCELLigence system
The xCELLigence system was used according to the instructions of the supplier (Roche
Applied Science and ACEA Biosciences). The xCELLigence system consists of four main com-
ponents: a Real time cell analysis (RTCA) analyser, a RTCA DP station, a RTCA computer
with integrated software and a disposable E-plate 16. Firstly, the optimal seeding concentration
for the proliferation and RTCA assay of HFF was determined. After seeding the total number
of the cells in 200 μL medium in each well of the E plate 16, the attachment, proliferation and
spreading of the cells were monitored every 15 min. All the experiments were carried out for
100 h. The obtained results were recalculated to the relative (%) value of the growth. The
method of the calculation was same as described for Staphylococcus aureus.
Preparation of erythrocytes for haematological analysis and
determination of glutathione
Human blood was obtained from the Department of Physiology, Faculty of Medicine, Masaryk
University, Czech Republic. We analysed the samples of healthy volunteers (n = 3), whereas
the written consent of blood donors was granted. The research has been approved by the Inde-
pendent ethics committee (No. 104MS451) at University Hospital, Brno, Czech Republic. The
blood samples of three healthy volunteers were collected in the tubes with heparin. The blood
samples were centrifuged for 10 min at 2000 rpm. After removing of plasma, the erythrocytes
together with platelets were diluted in phosphate buffer pH 7 in a ratio of 1:1. The number of
erythrocytes and platelets was determined using haematology analyser BC– 5800 (Mindray,
Shenzhen, China). Cisplatin or cisplatin encapsulated in liposomes (LipoCisPt) were added
to the erythrocytes mixture with platelets and various concentrations of the Pt derivatives
(PtNPs, PtNPs encapsulated in liposomes (LipoPtNPs)) in a ratio of 1:1 to reach the desired
concentrations (12.5, 25, 50, 100, 200 μg/mL of Pt and 0.6, 1.3, 2.5, 5 and 10 mg/mL of lipo-
somes) in the resulting mixture. The erythrocytes treated with the platinum compounds were
mixed with trifluoroacetic acid (TFA) in a ratio of 2:1 (100 μL of erythrocytes + 50 μL of 15%
TFA (v/v)). Subsequently, the mixture was homogenized using ultrasonic needle for 2 min and
vortexed for 10 min. After the centrifugation of the mixture for 20 min at 25 000 rpm, 20 μL of
the supernatant was used for chromatographic analysis.
Platinum nanoparticles and DNA
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Estimation of selected haematological parameters of erythrocytes
mixture with platelets exposed to platinum derivatives
The haematological analyses of the erythrocytes mixture with platelets exposed to platinum
derivatives encapsulated in liposomes or alone were performed using Haematology Analyser
BC-5800 (Mindray, Shenzen, China) coupled with flow cytometry. The number of erythro-
cytes and platelets was determined by impedance method. The flow cytometry together with
fluorescence-activated cell sorting was applied to determine the number of leukocytes. The his-
tograms of the erythrocytes mixture with platelets and Pt derivatives encapsulated in liposomes
or alone were recorded. The liposomes were visualised in the Baso channel as a red rhombus.
Determination of reduced and oxidized glutathione
Reduced (GSH) and oxidized (GSSG) glutathione were assayed using a high performance liq-
uid chromatography with electrochemical detection (HPLC-ED) according to Kleckerova
et al. [40] and Skladanka et al. [41]. Two solvent delivery pumps (Model 582 ESA Inc., Chelms-
ford, MA, USA) operating in a range of 0.001–9.999 mL.min-1, a column Zorbax eclipse AAA
C18 (150 × 4.6; 3.5 μm particle size; Agilent Technologies, Santa Clara, CA, USA) and a Cou-
lArray electrochemical detector (Model 5600A, ESA, USA) with one flow cell were used in this
experiment. The cell consists of four working carbon porous electrodes, each one with auxil-
iary and dry Pd/H2 reference electrodes. Both the detector and the reaction coil/column were
thermostated. Twenty microliters sample was injected using autosampler (Model 542 HPLC,
ESA, USA). The samples were stored in the carousel at 8˚C. The column was thermostated at
32˚C. The mobile phase was consisted of 80 mM TFA (A) and methanol (B). The compounds
of interest were separated by the following linear gradient: 0! 1 min (3% B, v/v), 1! 2 min
(10% B, v/v), 2! 5 min (30% B, v/v), 5! 6 min (98% B, v/v). The flow rate of the mobile
phase was 1 mL.min-1 and working electrode potential was set to 900 mV
Descriptive statistics
Data were processed using MICROSOFT EXCEL1 (USA) and STATISTICA.CZ Version 8.0
(Czech Republic). Results are expressed as mean ± standard deviation (S.D.) unless noted oth-
erwise (EXCEL1). Statistical significances of the differences were determined using STATIS-
TICA.CZ. Differences with p< 0.05 (labelled with “” in figures) were considered significant
and were determined by using of one way ANOVA test (particularly Scheffe test), which was
applied for means comparison.
Results
Characterization of PtNPs
The synthesized PtNPs as well as the liposomal formulations were characterized by particle-
size and Zeta potential measurement, transmission microscopy imaging, X-ray fluorescence
and UV/Vis spectrophotometry and atomic absorption spectrometry. The size of the PtNPs
determined by dynamic light scattering was mainly 6.5 nm in diameter with the Zeta potential
of -15 kV (Figures A and B in S1 Fig). The X-ray spectrum of the PtNPs was recorded and the
two characteristic peaks of Pt Kα (391 keV) and Pt Kβ (457 keV) were observed (Figures A in
S2 Fig). The presence of Pt was also confirmed by atomic absorption spectrometry. Subse-
quently, the stock solution of PtNPs with Pt concentration of 400 μg/mL was prepared and
used for further experiments. For these experiments, the stock solution was diluted creating
solutions of PtNPs with Pt concentrations ranging from 0 to 200 μg/mL of Pt in PtNPs. The
colour of the PtNPs was found to be brown. (Figures B and C in S1 Fig).
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PtNPs and CisPt interactions with DNA fragment from phage λ and Taq
DNA polymerase
The impact of PtNPs and CisPt on DNA was studied using PCR, DNA melting point (Tm)
analysis and Sanger sequencing. It was observed that the function of Taq DNA polymerase was
blocked by the PtNPs more effectively than by CisPt. The suggested scheme of the possible
mechanism is shown in Figs 1A and 2B.
In the first part of the experiment, it was observed that the PCR was stopped after the addi-
tion of at least 0.58 μg/mL PtNPs (Fig 1C). CisPt was studied in the same way and it was found
that 9.8 μg/mL CisPt was able to stop the PCR, which is nearly 17-times higher concentration
compared to that of the PtNPs (Fig 1D).
In the second part of the experiment, the changes in denaturation temperatures (Tm) were
studied. To observe these changes, 5 μg/mL DNA fragments from λ bacteriophage was mixed
with the PtNPs or CisPt (0–200 μg/mL). 0.1 μg/mL CisPt decreased the Tm by 7˚C compared
to the untreated control sample (77˚C). To reach the same effect on the Tm, 500 times more
PtNPs (50 μg/mL) was needed (Fig 1E). Based on this observation, it was concluded that
PtNPs interact more likely with polymerase than with the DNA.
In the third part of the experiment, the DNA fragment of λ bacteriophage (5 μg/mL) was
added to the CisPt or PtNPs solutions. These mixtures were subsequently dialysed to remove
the particles, which were not interacted or bound to DNA. The modified DNA was used for
Sanger sequencing reaction and the DNA was further analysed by the capillary gel electropho-
resis with laser-induced fluorescence detection. The fluorescence signals of the probed
Fig 1. (A) The suggested effects of PtNPs on polymerase chain reaction (PCR) is based on binding of PtNPs
to the Taq DNA polymerase, which leads to ceasing of PCR, (B) whereas CisPt primarily intercalates in DNA
structure and stops PCR by this way. The gel electrophoregrams of PCR product mixture with particular
concentration of (C) PtNPs (0.04–4 200 ng/mL of Pt) and (D) CisPt (0.04–42 000 ng/mL of Pt). (E) DNA
denaturation temperature affected by the 0–200 μg/mL of Pt derivatives. Fluorescence of labelled nucleotides
of DNA fragment after sequencing, which was influenced by (F) 0–20 μg/mL of PtNPs and (G) 0–0.33 μg/mL
of CisPt. For all measurement n = 3.
https://doi.org/10.1371/journal.pone.0180798.g001
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fragments were compared to the control DNA sample (without the addition of CisPt or
PtNPs). Fig 1F shows that the addition of 0.032 μg/mL PtNPs induced the increase in the fluo-
rescence signals of the fragments terminated with the dideoxynucleotides thymine (T), gua-
nine (G) or adenine (A) compared to the control sample. In the case of DNA fragments
terminated with the cytosine (C), the decreasing fluorescence was observed even when
0.032 μg/mL PtNPs were added.
After CisPt application, the fluorescence signals of DNA fragments terminated with T and
G decreased with the increasing concentration of CisPt. At the DNA fragments terminated
with C and A, the fluorescence signal firstly increased (at 0.07 μg/mL CisPt), followed by the
decrease in the fluorescence signal with the increasing concentration of CisPt as showed in Fig
1G. The signal decrease by 50% was reached after the application of PtNPs and CisPt in con-
centrations of 9.6 μg/mL and 0.13 μg/mL, respectively.
From the results of the second and third part of the experiment it is clear that the concen-
tration of the PtNPs should be 500 times (in the case of Tm change) and 74 times (in the case
of sequencing) higher than that of CisPt to achieve the same effect in DNA interaction. Con-
versely, as confirmed by the first experiment, where the PCR mixture contained together with
DNA and Taq DNA polymerase, the PCR was stopped by the addition of 580 ng/mL PtNPs,
which is 16.9 times lower concentration than that of CisPt. The results of these analyses have
unequivocally demonstrated that the PtNPs have a higher affinity to Taq DNA polymerase
than to DNA.
Fig 2. (A) The alkaline comet assay of nuclear DNA from human fibroblasts (HFF) treated with (a) cisplatin
(0–200 μg/mL of Pt) encapsulated in liposome LipoCisPt, (b) same concentration of CisPt only, (c) PtNPs
encapsulated in liposome LipoPtNPs and (d) free PtNPs. (B) The index of damage of CisPt and LipoCisPt. (C)
The index of damage of PtNPs and LipoPtNPs. (D) The nuclear DNA of human fibroblast and summarized
their total damage. For all measurement n = 3.
https://doi.org/10.1371/journal.pone.0180798.g002
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Comet assay
Based on previous experiments, we followed with the cell experiments, where we also tested
liposomal forms of both drugs to mimic targeted delivery. Therefore, the extent of DNA damage
in the individual somatic cells was studied. To assess the effect of both the PtNPs and CisPt on
nuclear DNA of eukaryotic cells the alkaline comet assay was used. The HFF cells in exponential
growth phase were exposed to bare and liposome-encapsulated Pt-derivatives in concentrations
of 0, 12.5, 25, 50, 100 and 200 μg/mL. Then, the cells were harvested and immobilized into aga-
rose, and lyzed. Later, the nuclei were electrophoresed and stained with ethidium bromide (Fig
2A). The microphotographs show the evident difference between the effect of CisPt (Fig 2Aa
and 2Ab) and PtNPs (Fig 2Ac and 2Ad) on the degradation of HFF nuclei. The index of the cell
nuclei damage was increased by the encapsulation of CisPt or PtNPs within liposome (Fig 2B
and 2C). The liposome-encapsulated PtNPs clearly showed the most intensive degradation
effects among all the studied drugs and formulations. As shown in Fig 2C, the platinum nano-
particles (25–200 μg/mL) encapsulated into liposome (LipoPtNPs) exhibited more than two-
times higher damage index than that of bare PtNPs. The comparison of the total index of the
DNA damage, i.e. mean of indexes of damage presented in Fig 2B and 2C, showed that the
PtNPs encapsulated within liposome damaged mostly the cell nuclei (Fig 2D).
The assessment of PtNPs and CisPt cytotoxicity and the effect of their
encapsulation in liposomes
In these experiments we focused on the assessment of the cytotoxicity of the platinum deriva-
tives and also on studying of the effect of their encapsulation in liposomes. Both S. aureus and
HFF were analysed after the application of the PtNPs and CisPt encapsulated in liposomes or
alone by the method of growth curves using Multiskan EX (S. aureus) and xCELLigence (HFF)
instruments.
Firstly, the growth curves of the bacterial culture were measured after the addition of the
Pt-derivatives encapsulated in liposome or alone in concentrations of 100 μg/mL of Pt. The
obtained results were recalculated to relative absorbance value, thus, the control growth curve
without the addition of the platinum derivatives was considered as 100% (Fig 3Aa). The values
lower than 100% indicated relative cell death. The highest cytotoxic effect (100% dead cells)
was observed in case of CisPt (Fig 3Ac), whereas a similar effect was achieved after the addition
of LipoPtNPs, (Fig 3Ad). After the application of LipoPtNPs, the relative growth rate was
found to be decreased for 53% (i.e. 53% dead cells) as compared to that of CisPt. The cytotoxic-
ity of the PtNPs was found to be the lowest among all the drugs during the first 8 h of the treat-
ment (Fig 3Ae), but after 24 h their cytostatic effect was found to be the third most intensive
and its value was 20% higher and 30% lower than that of LipoCisPt and CisPt respectively. The
results are summarized in Fig 3B, where the cytotoxicity of the Pt-derivatives encapsulated in
liposomes or alone are shown.
The growth of HFF was monitored by xCELLigence method in the presence of the platinum
derivatives (Fig 3C). The growth of the cells was expressed as percentage of control, thus, the
growth curve of the control cells cultivated without the addition of any drug corresponded to
100%. For all tested platinum derivatives, the decrease of the cell growth during the cultivation
was observed with exception of PtNPs (Fig 3Ce), where the growth of HFF was found to be
stimulated during the first 50 h, but after 50 h the growth inhibition occurred. The highest
cytostatic effect (100% decrease) was recorded for CisPt (Fig 3Cc) and LipoCisPt (Fig 3Cb).
The PtNPs exhibited markedly lower cytotoxic effect compared to CisPt. After liposome
encapsulation, the LipoPtNPs the rate if cell growth inhibition was higher, compared to bare
PtNPs. The inhibition activity of LipoPtNPs after 100 h was comparable to the bare PtNPs
Platinum nanoparticles and DNA
PLOS ONE | https://doi.org/10.1371/journal.pone.0180798 July 12, 2017 10 / 19
(Fig 3Cd). The summary of the obtained results is shown in Fig 3D, where the cytotoxicity of
the Pt-derivatives encapsulated in liposomes or alone is shown. Based on these results, CisPt
had the highest cytostatic and cytotoxic effect for both S. aureus and HFF. The encapsulation
of cisplatin in liposomes decreased both cytostatic and cytotoxic effects of cisplatin for the bac-
terial cells as well as for HFF. The PtNPs were found to be more effective in the bacterial cells
than in HFF. The encapsulation in liposomes increased both the cytostatic and cytotoxic
effects of the PtNPs, where one may suggest one of the following four mechanisms of lipo-
some-cell interaction by which liposomes deliver their content in cells can occur: i) adsorption
followed by extracellular release of liposome content; ii) endocytosis clathrin-(in) dependent;
iii) lipid exchange by transfer of lipophilic compounds from the liposomal bilayer to the cell
membrane and iv) fusion with the intracellular membrane.
The influence of Pt derivatives encapsulated in liposomes and alone on
erythrocytes mixture with platelets (flow cytometry and GSH/GSSG
ratio)
The commonly used cytostatics such as CisPt as well as their new alternatives such as PtNPs
are often administered intravenously and therefore they may interact with erythrocytes and
platelets.
The influence of the platinum derivatives encapsulated in liposomes or alone on human
erythrocytes mixed with platelets was studied by flow cytometry using haematology analyser and
the oxidative stress was determined by GSH/GSSG ratio. The mixtures of the erythrocytes and
Fig 3. The effect of platinum derivatives on both bacterial and human cells after application of
platinum derivatives alone or encapsulated in liposomes. Relative change of growth rate of (A) S. aureus
bacterial culture and (C) HFF after treatment with Pt-derivatives (100 μg/mL of Pt) during 24 h (bacterial
culture) and 100 h (HFF) long experiments. (a) Cell culture without any treatment, (b) LipoCisPt, (c) CisPt, (d)
LipoPtNPs and (e) PtNPs. Percentage survival of (B) S. aureus bacterial culture and (D) human foreskin
fibroblasts (HFF) after 24 and 100 h of treatment with Pt-derivatives (100 μg/mL of Pt) alone and
encapsulated in liposomes. For all measurement n = 3.
https://doi.org/10.1371/journal.pone.0180798.g003
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platelets were exposed to LipoCisPt, CisPt, LipoPtNPs and PtNPs in concentrations of 0, 12.5,
25, 50, 100 and 200 μg/mL of Pt for 16 h. The concentrations of the liposomes in LipoPtNPs and
LipoCisPt were as follows: 0, 0.6, 1.3, 2.5, 5, and 10 mg/mL. The histograms of the mixture and
the Pt derivatives encapsulated in liposomes or alone were recorded by a haematology analyser.
The liposomes were visualised in the Baso channel as a red rhombus (Fig 4A). No significant
interaction was found for any of the Pt derivatives and the erythrocyte-platelet mixture.
The PtNPs encapsulated in liposomes were prepared and subsequently diluted decreasing
the concentration of both components concurrently. The effect of this treatment is shown in
Fig 4Ac.
The GSH and GSSG concentrations were determined by HPLC-ED (Fig 4B–4E). After
treatment by all the Pt derivatives, a decrease in the GSH/GSSG ratio was observed that indi-
cates the increasing amount of the oxidative stress in the erythrocytes. From Fig 4F, it can be
clearly seen that LipoCisPt and CisPt caused higher oxidative stress than LipoPtNPs and
PtNPs. By the statistical analysis using Lord´s T test, it was proven that compounds containing
CisPt statistically differ from compounds containing PtNPs. However, the statistically signifi-
cant difference was detected also between CisPt and PtNPs as well as between LipoCispt and
LipoPtNPs. At the confidence level of 0.05.
Discussion
In the present experiment, the effects of PtNPs, or CisPt alone and encapsulated in liposomes
(LipoPtNPs or LipoCisPt) on bacterial cultures (Staphylococcus aureus), HFF, erythrocytes and
Fig 4. Selected haematological parameters of erythrocytes mixture with platelets and oxidative stress
(GSH/GSSG) in the mixture after application of Pt derivatives encapsulated in liposomes or alone in
concentrations 0, 12.5, 25, 50, 100 and 200 μg/mL of Pt and 0, 0.6, 1.3, 2.5, 5 and 10 mg/mL of
liposomes. (A) Histograms of (a) erythrocytes and (b) platelets, and (c) visualisations of liposomes in the
Baso channel after application of LipoCisPt, CisPt, LipoPtNPs and PtNPs. GSH/GSSG ratio of erythrocytes
mixture with platelets in the same concentrations as in A—(B) LipoCisPt, (C) CisPt, (D) LipoPtNPs, and (E)
PtNPs. (F) Mean of GSH/GSSG ratio. For all measurement n = 3, significant difference is indicated by
*p<0.05.
https://doi.org/10.1371/journal.pone.0180798.g004
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DNA (PCR product of Xis gene of λ phage) were studied. The platinum complexes are the
active substance used as effective cytostatics [14]. Hundreds of Pt(II) and Pt(IV) complexes
have been synthesized since the discovery the antibacterial effects of platinum in 1965 [42–44].
The effect of the platinum complexes (cisplatin, carboplatin and oxaliplatin) is most probably
based on their covalent binding with DNA bases [45, 46] forming intra- and interstrand cross-
links, DNA—protein crosslinks, and monoadducts with DNA [47]. DNA secondary structures
can block transcription and replication with subsequent apoptosis [48]. Pt drugs enter cells
mainly via passive diffusion, although some evidence of its active transport by Ctr1 system
involved in the maintaining of copper homeostasis was reported (Fig 5A) [49–52]. Another
possibility is the intake of the nanoparticles via endocytosis [53]. Cisplatin-induced DNA dam-
age activates ATR kinase, which triggers the effector molecules. One of the ATR kinase targets
is a tumour suppressor protein p53, which is phosphorylated by the kinase on serine 15. This
phosphorylation causes the decrease of p53 affinity to its negative regulator Mdm-2, which
leads to an increased p53 concentration. The protein p53 then initiates the transcription of p21
gene, which inhibits the cyclin-dependent kinases Cdk2 and Cdk4 and consequent arrests the
cell cycle. p53 also induces the expression of pro-apoptotic members of Bcl-2 family such as
Bax, Puma and Noxa in response of the activation of mitochondrial apoptotic pathway.
On the mitochondrial surface, these pro-apoptotic proteins meet the anti-apoptotic Bcl-2
family members. The main determinant of cisplatin-induced DNA damage is the ratio of pro-
apoptotic and anti-apoptotic proteins. The majority of the pro-apoptotic signals lead to the
release of cytochrome c from mitochondria followed by the activation of cysteine caspases
selectively degrading the target proteins. Initiator caspases (Casp-8, 9 and 10) activate the
effector caspases (Casp-3, 6 and 7). Casp-8 and Casp-9 are activated by outer pathway through
the death receptors and inner mitochondrial pathway respectively. Both Casp-8 and 9 then
activate Casp-3, which is responsible for intrinsic apoptotic process [53, 55, 56].
Among thousands of published papers aimed at the mentioned platinum-based cytostatics,
only few can be found with the physiological action of the platinum nanoparticles [57, 58]. Some
papers inform about the antioxidant properties of the PtNPs. Kajita et al. reported that PtNPs
eliminated the anion radicals and hydrogen peroxide by a mechanism similar to superoxide-dis-
mutase and catalase action [18]. Kim et al. [59] also confirmed the antioxidant function of PtNP,
s which were shown to reduce the oxidative stress in murine osteoclasts. Onizawa et al. [60],
studied the antioxidant activity of PtNPs in murine lungs after exposition to cigarette smoke. In
a separate experiment, synthetic PtNPs at ppb levels were shown to extend the nematode lifespan
and scavenge ROS which was induced by paraquat treatment in the nematode [61]. The anti-
inflammatory effects of platinum nanoparticles on the lipopolysaccharide-induced inflammatory
response in RAW 264.7 macrophages were determined by Rehman et al. [62].
Fig 5. (A) Effect of CisPt on the somatic cell. (B) Proposed effect of PtNPs on the somatic cell.
Figure prepared according to [54].
https://doi.org/10.1371/journal.pone.0180798.g005
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Oh et al. reported the synthesis of the PtNPs of a diameter of 4.8 nm [29], which were char-
acterized by X-ray and UV/Vis spectrophotometry [63]. In this work, the PtNPs were shown
(using different techniques like PCR, DNA sequencing and denaturation) to inhibit the Taq
DNA polymerase and affect the secondary structure of DNA in higher concentrations. Differ-
ent papers on the interaction of heavy metals (Cu, Pb, and Cd) with DNA polymerase and thus
inhibition of PCR were previously published [64, 65]. Our findings are consistent with earlier
reports emphasizing intracellular release of Pt2+ ions from PtNPs, which could block cell divi-
sion by binding with DNA [66]. The intracellular interactions of the PtNPs with bacterial
DNA (Salmonella Enteritidis) were also previously reported [27] and it was shown using DNA-
binding fluorochrome that one hour treatment of Salmonella enteritidis with PtNPs removed
part of the DNA from the bacterial cell [27]. Shukla et al. showed that the nanoparticles tend to
aggregate in the liposomes [67]. The aggregation of the PtNPs in liposomes may be responsible
for the observed PtNPs cytotoxicity. This phenomenon can be explained by the oxidation of Pt
by hydrogen peroxide according to the equation: Pt + H2O2 + 2H
+! Pt2+ + 2H2O [67]. The
different mechanisms of CisPt and PtNPs action were found by single cell gel electrophoresis
(comet assay) in this study. This method allows us to detect DNA damage on the single cell
level [68]. Different modes of HFF nuclei degradation were observed after the treatment with
CisPt or PtNPs, where the PtNPs were found to cause a higher degree of DNA degradation
compared to CisPt. This finding may be caused by the fact that the alkaline comet assay is
more sensitive to dsDNA breakage than to ssDNA breakage. In case of CisPt, ssDNA breakage
[69], and covalent binding to DNA and interstrand crosslink [45] were observed as a result of
a direct interaction with the DNA. The dsDNA breakages were caused rather by the PtNPs-
induced Pt2+ ions formed during the incubation of the PtNPs with DNA [23].
The interactions of the Pt-derivatives with DNA might cause the arrest of cell cycle or have
mutagenic effect [70]. The results suggest that p53 was activated in PtNPs treated cells due to
the genotoxic stress with subsequent activation of p21 leading to a proliferating cell nuclear
antigen-mediated growth arrest and apoptosis (Fig 5B) [54]. In this study, an attention was
also paid to the antibacterial effects of the nanomaterials [71]. The PtNPs seemed to be a signif-
icant antibacterial agent [26, 72]. According to Chwalibog et al. PtNPs cause the degradation
of cytoplasmic membrane and bacterial cell wall [26]. Our results indicated that the encapsula-
tion of the nanoparticles in liposomes may lead to a more effective delivery of the nanoparti-
cles as well as the disruption of the cellular membranes and thus increase their cytotoxicity
and antibacterial action [73, 74].
In this work, the inhibition of bacterial and HFF growth by PtNPs and CisPt alone and
encapsulated in liposome was compared by the method of growth curves and it was found that
the inhibition effect of LipoPtNPs on S. aureus cells was higher compared to bare PtNPs. The
inhibition of both keratinocytes and bacterial growth by PtNPs was also reported previously
by Konieczny et al. [53], where the authors found an increased DNA damage and caspase 9
activity in human keratinocytes and a size-dependent inhibition effect of PtNPs on S. aureus
and E. coli using a colony-reduction assay. No differences between PtNPs and CisPt action on
human erythrocytes was found by haematological analyser. Both the bare and encapsulated
PtNPs were found to cause significantly lower oxidative stress in the erythrocytes compared to
the bare and encapsulated CisPt (as measured by GSH/GSSG ratio).
Conclusions
In this paper, we showed that PtNPs primarily inhibit the activity of Taq DNA polymerase and
damage to the DNA structure. We tend to believe that this effect together with the transition
of PtNPs to Pt2+ causes mutagenicity and increases DNA damage compared to CisPt. The
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cytotoxic effect of the PtNPs may be increased by their encapsulation in liposome. The results
suggest that the activation of p53 in PtNPs treated cells was caused by the genotoxic stress with
subsequent activation of p21 leading to a proliferating cell nuclear antigen-mediated growth
arrest in S phase and following apoptosis [54]. It is conceivable that the PtNPs with the effec-
tive antitumor activity may provide an alternative treatment for cancer.
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